Two Cognitive Peptides Engineered a World Apart from Western Pharma

Long before Western nootropics culture existed, Soviet-era researchers at the Institute of Molecular Genetics in Moscow were deliberately engineering peptides to influence cognition. Two of those compounds, Semax and Selank, are still actively studied today, and they share a design principle: both were built with a small molecular modification that resists rapid enzymatic breakdown, extending how long the signal persists in the body — a deliberate engineering choice rather than an incidental discovery.

Semax is derived from a fragment of adrenocorticotropic hormone (ACTH), a stress-response hormone, but modified to remove the hormonal activity while preserving a separate effect on the nervous system. Research has associated it with increased expression of BDNF and NGF — brain-derived neurotrophic factor and nerve growth factor, two proteins central to neuronal growth, plasticity, and survival. It's been studied in the context of focus, memory, and neuroprotection.

Selank takes a different route. It's derived from a naturally occurring immune-signaling peptide and has been studied primarily as an anxiolytic — a compound that reduces anxiety — working through interaction with the GABA system, the brain's primary inhibitory neurotransmitter pathway. Unlike many older anxiolytics, the research on Selank describes an anxiety-reducing effect without the sedation typically associated with GABA-acting drugs.

Together, the two compounds are often discussed as complementary — one oriented toward increasing signal and drive, the other toward reducing noise and stress — though it's worth noting they haven't necessarily been studied together in controlled human trials at scale.

The honest limitation with both compounds is the evidence base itself. Decades of research exist, but a substantial portion of it comes from Russian clinical and animal studies that haven't been replicated in large, independently conducted Western trials. That's not evidence the findings are wrong, but it does mean the evidence base is narrower and less internationally validated than compounds that have gone through the standard Western regulatory and academic replication pipeline.

Why this matters for tracking: cognitive and mood effects are some of the hardest self-reported outcomes to evaluate objectively, since baseline stress, sleep, and life circumstances shift constantly. If you're paying attention to compounds in this category, structured tracking of mood, focus, and sleep quality over time — rather than relying on memory of how a given week felt — is what actually lets you separate a real effect from noise.